Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06CZS
|
||||
| Former ID |
DCL001126
|
||||
| Drug Name |
V85546
|
||||
| Indication | Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10:C11, C44, K75.9, M00-M25] | Discontinued in Phase 1 | [1] | ||
| Therapeutic Class |
Antiinflammatory Agents
|
||||
| Company |
Vernalis
|
||||
| Target and Pathway | |||||
| Target(s) | MMP-12 | Target Info | Inhibitor | [2] | |
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL5 Signaling Pathway | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| WikiPathways | TGF beta Signaling Pathway | ||||
| Degradation of collagen | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020392) | ||||
| REF 2 | Clinical pipeline report, company report or official report of Vernalis. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.